Conferences - Results from #80

Viewing 81-100 of 11775 articles

IBCN 2024: Systematic Evaluation of Differentially Expressed Genes Associated with Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer

IBCN 2024: Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides using a deep learning approach in the VESPER Trial

IBCN 2024: Oncolytic Virotherapy Expressing a Novel TLR Agonist and IL-15 for the Treatment of NMIBC

IBCN 2024: Spatial Proteomics and Transcriptomics Reveal an Altered Immune Cell Landscape in Bladder Cancer Patients Unresponsive to BCG Treatment

IBCN 2024: Molecular Subtypes and Outcomes in the VESPER Trial

IBCN 2024: Molecular Subtyping in 2024: The LUMBER-NAC Trial

IBCN 2024: GUSTO Trial

IBCN 2024: ADC Toxicity, Management and Clinical Trial Updates

IBCN 2024: Benefit of Whole-Pelvis Radiation for Patients with Muscle Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis

IBCN 2024: Influence of Immortal Time Bias and Conditional Survival on the Comparison of Radical Cystectomy Versus Trimodality Therapy for Muscle Invasive Bladder Cancer

IBCN 2024: Using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Preliminary Analysis from the BOND-003 Trial

IBCN 2024: EG-70 (Detalimogene Voraplasmid), a Novel, Non-Viral, Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS: Preclinical Characterization and Translation into the Clinic

IBCN 2024: Augmented Cystoscopy with Deep Learning

IBCN 2024: The Value of mpMRI to Assist in Decision Making in Muscle Invasive Bladder Cancer

IBCN 2024: TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Patients with BCG Unresponsive High-Risk NMIBC: Results from SunRISe-1

IBCN 2024: TAR-200 Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients With Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Platinum-Based Chemotherapy: Interim Analysis of SunRISe-4

IBCN 2024: AI in Bladder Cancer: The Good, the Bad, and the Ugly

IBCN 2024: A Randomized Phase II Trial Comparing Single Dose Perioperative Instillation of Intravesical Gemcitabine Versus Mitomycin-C Following Complete Resection of Non-Muscle Invasive Bladder Cancer: Evaluation of Efficacy and Tolerance

IBCN 2024: AI-Enabled Bladder Cancer Grading: Externally Validating Quantitative Nuclear Features and Demonstrating Their Potential to Better Predict Time to Recurrence

IBCN 2024: Validation of Artificial Intelligence-Powered Pathology Assay and Comparison to EAU 2021 Guidelines on Prediction of Muscle Invasive Progression Post BCG in an International 12 Center Cohort

1
2
3
4
5
6
7
8
9
10